China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020. The long-awaited approval comes as infections have fallen sharply across China since it suddenly dropped its strict "zero-COVID" curbs in December, making the sales outlook for the newly approved vaccine moderate.
